MicroRNA‐299‐3p inhibits cell proliferation, motility, invasion and angiogenesis via VEGFA in upper tract urothelial carcinoma

BACKGROUND Upper tract urothelial carcinoma (UTUC) is a rare tumor with extraordinarily different features between Eastern and Western countries. Vascular endothelial growth factor-A (VEGFA) was originally identified as a secreted signaling protein and regulator of vascular development and cancer progression. In this study, we aimed to elucidate the molecular mechanisms underlying the regulation of VEGFA by microRNA in UTUC. METHODS VEGFA expression was evaluated by immunohistochemistry in 140 human UTUC tissue samples. Next, we assessed the regulatory relationship between VEGFA and miR-299-3p by real-time PCR, western blotting, ELISA and dual-luciferase reporter assays using two UTUC cell lines. The role of miR-299-3p/VEGFA in cell proliferation, motility, invasion, and tube formation was analyzed in vitro. RESULTS High VEGFA expression was significantly associated with tumor stage, grade, distant metastasis and cancer-related death and correlated with poor progression-free and cancer-specific survival. VEGFA knockdown repressed proliferation, migration, invasion and angiogenesis in UTUC cell lines. miR-299-3p significantly reduced VEGFA protein expression and miR-299-3p overexpression inhibited VEGFA mRNA and protein expression by directly targeting its 3'-UTR. Functional studies indicated that VEGFA overexpression reversed the miR-299-3p-mediated suppression of tumor cell proliferation, migration, invasion and angiogenesis. In addition, miR-299-3p/VEGFA suppressed cellular functions in UTUC by modulating the expression of P18 and cyclin E2. CONCLUSIONS Our findings suggest that miR-299-3p possibly suppresses UTUC cell proliferation, motility, invasion and angiogenesis via VEGFA. VEGFA may act as a prognostic predictor, and both VEGFA and miR-299-3p could be potential therapeutic targets for UTUC.

[1]  T. Chan,et al.  Angiogenesis Driven by the CEBPD–hsa-miR-429–VEGFA Signaling Axis Promotes Urothelial Carcinoma Progression , 2022, Cells.

[2]  Wen-Jeng Wu,et al.  MicroRNA-375-3p Suppresses Upper Tract Urothelial Carcinoma Cell Migration and Invasion via Targeting Derlin-1 , 2022, Cancers.

[3]  Fei Tian,et al.  ADAMTS8 inhibited lung cancer progression through suppressing VEGFA. , 2022, Biochemical and biophysical research communications.

[4]  F. Liu,et al.  Targeting PELP1 Attenuates Angiogenesis and Enhances Chemotherapy Efficiency in Colorectal Cancer , 2022, Cancers.

[5]  Y. Man,et al.  Downregulation of miR-375 contributes to ERBB2-mediated VEGFA overexpression in esophageal cancer , 2021, Journal of Cancer.

[6]  Rumei Li,et al.  CNN1 regulates the DKK1/Wnt/β-catenin/c-myc signaling pathway by activating TIMP2 to inhibit the invasion, migration and EMT of lung squamous cell carcinoma cells , 2021, Experimental and therapeutic medicine.

[7]  Hongwei Chen,et al.  Long non-coding RNA USP30-AS1 aggravates the malignant progression of cervical cancer by sequestering microRNA-299-3p and thereby overexpressing PTP4A1 , 2021, Oncology letters.

[8]  Chun-Chieh Huang,et al.  The Prognostic Impact of Tumor Architecture for Upper Urinary Tract Urothelial Carcinoma: A Propensity Score-Weighted Analysis , 2021, Frontiers in Oncology.

[9]  Mengming Michael Dong,et al.  LncRNA MIR205HG regulates melanomagenesis via the miR-299-3p/VEGFA axis , 2021, Aging.

[10]  Shaofeng Lin,et al.  LINC00673 Represses CDKN2C and Promotes the Proliferation of Esophageal Squamous Cell Carcinoma Cells by EZH2-Mediated H3K27 Trimethylation , 2020, Frontiers in Oncology.

[11]  Anping Li,et al.  Distinct Roles of VEGFA and ANGPT2 in Lung Adenocarcinoma and Squamous Cell Carcinoma , 2020, Journal of Cancer.

[12]  K. Bensalah,et al.  PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. , 2019, Urologic oncology.

[13]  T. Halski,et al.  Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer , 2019, Current pharmaceutical biotechnology.

[14]  Kunning Wang,et al.  MiR-299-3p functions as a tumor suppressor via targeting Sirtuin 5 in hepatocellular carcinoma. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[15]  Ruiyang Zhao,et al.  MicroRNA-299-3p regulates proliferation, migration and invasion of human ovarian cancer cells by modulating the expression of OCT4. , 2018, Archives of biochemistry and biophysics.

[16]  Qiang Yuan,et al.  Role of VEGFA gene polymorphisms in colorectal cancer patients who treated with bevacizumab , 2017, Oncotarget.

[17]  Jin-bo Jiang,et al.  MicroRNA-299-3p suppresses proliferation and invasion by targeting VEGFA in human colon carcinoma. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[18]  H. Cai,et al.  Long non-coding RNA taurine upregulated 1 enhances tumor-induced angiogenesis through inhibiting microRNA-299 in human glioblastoma , 2017, Oncogene.

[19]  Jeffrey T Leek,et al.  Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown , 2016, Nature Protocols.

[20]  D. Frezzetti,et al.  Vascular Endothelial Growth Factor A Regulates the Secretion of Different Angiogenic Factors in Lung Cancer Cells , 2016, Journal of cellular physiology.

[21]  Y. Li,et al.  Identification of a six microRNA signature as a novel potential prognostic biomarker in patients with head and neck squamous cell carcinoma , 2016, Oncotarget.

[22]  Yong Peng,et al.  The role of MicroRNAs in human cancer , 2016, Signal Transduction and Targeted Therapy.

[23]  F. Montorsi,et al.  Survival after nephroureterectomy for upper tract urothelial carcinoma: A population‐based competing‐risks analysis , 2014, International journal of urology : official journal of the Japanese Urological Association.

[24]  David A. Green,et al.  Urothelial carcinoma of the bladder and the upper tract: disparate twins. , 2013, The Journal of urology.

[25]  D. Spandidos,et al.  Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder , 2012, Oncology reports.

[26]  J. Lindebjerg,et al.  Prognostic importance of VEGF-A haplotype combinations in a stage II colon cancer population. , 2012, Pharmacogenomics.

[27]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[28]  V. Margulis,et al.  Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. , 2012, European urology.

[29]  Arthur P. Grollman,et al.  Aristolochic acid-associated urothelial cancer in Taiwan , 2012, Proceedings of the National Academy of Sciences.

[30]  J. Bondaruk,et al.  Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer , 2012, Cell cycle.

[31]  J. Burchard,et al.  RNA-Induced Silencing Complex-Bound Small Interfering RNA Is a Determinant of RNA Interference-Mediated Gene Silencing in Mice , 2011, Molecular Pharmacology.

[32]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[33]  Wen-Jeng Wu,et al.  Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. , 2010, European urology.

[34]  F. Montorsi,et al.  Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. , 2009, European journal of cancer.

[35]  M. Won,et al.  A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway. , 2009, Biochemical and biophysical research communications.

[36]  R. Medema,et al.  P18 is a tumor suppressor gene involved in human medullary thyroid carcinoma and pheochromocytoma development , 2009, International journal of cancer.

[37]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[38]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[39]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[40]  V. Ambros The functions of animal microRNAs , 2004, Nature.

[41]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[42]  G. Goodall,et al.  Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements. , 1999, Molecular biology of the cell.

[43]  Y. Xiong,et al.  Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6. , 1999, Cancer research.

[44]  S. Campbell,et al.  Molecular mediators of angiogenesis in bladder cancer. , 1998, Cancer research.

[45]  James M. Roberts,et al.  Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.